Article information
Abstract
Anemia is very common entity or comorbidity in surgical patients. Its management involves a multidisciplinary approach with the aim of optimizing the available therapeutic resources with individualized care for each clinical situation. Rational use of blood transfusions, iron therapy (oral and intravenous), erythropoiesis stimulating agents and other therapeutic alternatives by physicians must achieve maximal benefit with minimal complications for our patients. This review article summarizes the main characteristics of anemia, iron metabolism, erythropoiesis and therapeutic alternatives from a surgical perspective in the light of present knowledge
Keywords:
Complex incisional hernia
Surgical treatment
Double mesh
Resumen
La anemia representa una entidad o comorbilidad extremadamente frecuente dentro de la población de pacientes quirúrgicos. Su manejo implica un abordaje multidisciplinar con el fin de optimizar los recursos terapéuticos disponibles de forma individualizada en cada situación clínica. El uso racional por parte del clínico de transfusiones sanguíneas, ferroterapia (oral y endovenosa), agentes estimuladores de la eritropoyesis y otras alternativas terapéuticas ha de proporcionar el máximo beneficio a nuestros pacientes con las mínimas complicaciones posibles. El presente artículo de revisión resume las principales características de la anemia, metabolismo férrico, eritropoyesis y alternativas terapéuticas desde una perspectiva quirúrgica, a la luz de los conocimientos actuales.
Palabras clave:
Anemia
Hierro
Transfusión
Full text is only aviable in PDF
References
[1.]
E. Bisbe, C. Rodríguez, A. Ruiz, M. Sáez, J. Castillo, X. Santiveri.
Uso preoperatorio de hierro endovenoso. Una nueva terapéutica en medicina transfusional.
Rev Esp Anestesiol Reanim, 52 (2005), pp. 536-540
[2.]
C. Gasche, A. Berstad, R. Befrits, C. Beglinger, A. Dignass, K. Erichsen, et al.
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases.
Inflamm Bowel Dis, 13 (2007), pp. 1545-1553
[3.]
H. Gaskell, S. Derry, R. Andrew Moore, H.J. McQuay.
Prevalence of anaemia in older persons: systematic review.
BMC Geriatr, 8 (2008), pp. 1
[4.]
K.V. Patel.
Epidemiology of anemia in older adults.
Semin Hematol, 45 (2008), pp. 210-217
[5.]
X. Dong, C. Mendes de Leon, A. Artz, Y. Tang, R. Shah, D. Evans.
A population-based study of hemoglobin, race, and mortality in elderly persons.
J Gerontol A Biol Sci Med Sci, 63 (2008), pp. 873-878
[6.]
F. Landi, A. Russo, P. Danese, R. Liperoti, C. Barillaro, R. Bernabei, et al.
Anemia status, hemoglobin concentration, and mortality in nursing home older residents.
J Am Med Dir Assoc, 8 (2007), pp. 322-327
[7.]
M. Muñoz, S.R. Leal-Noval, J.A. García-Erce, E. Naveira.
Prevalencia y tratamiento de la anemia en el paciente crítico.
Med Intensiva, 31 (2007), pp. 388-398
[8.]
O.M. Theusinger, P.F. Leyvraz, U. Schanz, B. Seifert, D.R. Spahn.
Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: efficacy and limits: a prospective study.
Anesthesiology, 107 (2007), pp. 923-927
[9.]
N. Agarwal, J.T. Prchal.
Erythropoietic agents and the elderly.
Semin Hematol, 45 (2008), pp. 267-275
[10.]
T.S. Dharmarajan, A. Pankratov, E. Morris, S. Qurashi, G. Law, S. Phillips, et al.
Anemia: its impact on hospitalizations and length of hospital stay in nursing home and community older adults.
J Am Med Dir Assoc, 9 (2008), pp. 354-359
[11.]
B.W. Penninx, H.J. Cohen, R.C. Woodman.
Anemia and cancer in older persons.
J Support Oncol, 5 (2007), pp. 107-113
[12.]
M. Kobune, J. Kato, Y. Niitsu.
Anemia in patients with cancer.
Nippon Rinsho, 66 (2008), pp. 524-529
[13.]
S. Kulnigg, S. Stoinov, V. Simanenkov, L.V. Dudar, W. Karnafel, L.C. Garcia, et al.
A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
Am J Gastroenterol, 103 (2008), pp. 1182-1192
[14.]
N.C. Andrews.
Forging a field: the golden age of iron biology.
Blood, 112 (2008), pp. 219-230
[16.]
M. Alleyne, M.K. Horne, J.L. Miller.
Individualized treatment for iron-deficiency anemia in adults.
Am J Med, 121 (2008), pp. 943-948
[17.]
H.L. Corwin, A. Gettinger, R.G. Pearl, M.P. Fink, M.M. Levy, E. Abraham, et al.
The CRIT Study: Anemia and blood transfusion in the critically ill−current clinical practice in the United States.
Crit Care Med, 32 (2004), pp. 39-52
[18.]
F.A. Khan, A.N. Shukla, S.C. Joshi.
Anaemia and cancer treatment: a conceptual change.
Singapore Med J, 49 (2008), pp. 759-764
[19.]
A. Pelegrí.
Impact of erythropoietin treatment on the quality of life of oncologic patients.
Clin Transl Oncol, 9 (2007), pp. 645-651
[20.]
R.N. Schwartz.
Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols.
Am J Health Syst Pharm, 64 (2007), pp. S5-S13
[21.]
E. Guardiola, F. Morschhauser, J.J. Zambrowski, E.C. Antoine.
Management of anaemia in patient with cancer: results of the F-ACT study (French Anaemia Cancer Treatment).
Bull Cancer, 94 (2007), pp. 907-914
[22.]
J.L. Pontón, E. Feliu, P. Modamio, E.L. Mariño, A. Font, C. Lezcano, et al.
Estudio de la efectividad de tres esquemas de administración de factores estimuladores de la eritropoyesis en pacientes con anemia asociada a quimioterapia por una neoplasia sólida o hematológica.
Med Clin (Barc), 131 (2008), pp. 447-451
[23.]
S.S. Chohan, F. McArdle, D.B. McClelland, S.J. Mackenzie, T.S. Walsh.
Red cell transfusion practice following the transfusion requirements in critical care (TRICC) study: prospective observational cohort study in a large UK intensive care unit.
Vox Sang, 84 (2003), pp. 211-218
[24.]
H.L. Corwin.
Anemia and blood transfusion in the critically ill patient: role of erythropoietin.
Crit Care, 8 (2004), pp. S42-S44
[25.]
C. Chant, G. Wilson, J.O. Friedrich.
Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study.
Crit Care, 10 (2006), pp. R140
[26.]
F. De la Morena, J.P. Gisbert.
Anemia and inflammatory bowel disease.
Rev Esp Enferm Dig, 100 (2008), pp. 285-293
[27.]
P. Beris, M. Muñoz, J.A. García-Erce, D. Thomas, A. Maniatis, P. Van der Linden.
Perioperative anaemia management: consensus statement on the role of intravenous iron.
Br J Anaesth, 100 (2008), pp. 599-604
[28.]
A. Serrablo, E. Urbieta, J. Carcelén-Andrés, J. Ruiz, J. Rodrigo, M. Izuel, et al.
Hierro por vía intravenosa en cirugía general.
Cir Esp, 78 (2005), pp. 195-197
[29.]
W.P. Den Elzen, R.G. Westendorp, M. Frölich, W. De Ruijter, W.J. Assendelft, J. Gussekloo.
Vitamin B12 and folate and the risk of anemia in old age: the Leiden 85-Plus Study.
Arch Intern Med, 168 (2008), pp. 2238-2244
[30.]
P. Sharp, S.K. Srai.
Molecular mechanisms involved in intestinal iron absorption.
World J Gastroenterol, 13 (2007), pp. 4716-4724
[31.]
D.M. Frazer, G.J. Anderson.
Iron imports. I. Intestinal iron absorption and its regulation.
Am J Physiol Gastrointest Liver Physiol, 289 (2005), pp. G631-G635
[32.]
E. Harju.
Empty iron stores as a significant risk factor in abdominal surgery.
JPEN J Parenter Enteral Nutr, 12 (1988), pp. 282-285
[33.]
S. Mullick, U. Rusia, M. Sikka, M.A. Faridi.
Impact of iron deficiency anaemia on T lymphocytes & their subsets in children.
Indian J Med Res, 124 (2006), pp. 647-654
[34.]
N.C. Andrews.
Disorders of iron metabolism.
N Engl J Med, 341 (1999), pp. 1986-1995
[35.]
J. Wally, S.K. Buchanan.
A structural comparison of human serum transferrin and human lactoferrin.
Biometals, 20 (2007), pp. 249-262
[36.]
T. Ganz.
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.
Blood., 102 (2003), pp. 783-788
[38.]
M. Muñoz Gómez, A. Campos Garríguez, J.A. García Erce, G. Ramírez Ramírez.
Fisiopatología del metabolismo del hierro: implicaciones diagnósticas y terapéuticas.
Nefrologia, 25 (2005), pp. 9-19
[39.]
D. Darshan, G.J. Anderson.
Liver-gut axis in the regulation of iron homeostasis.
World J Gastroenterol, 13 (2007), pp. 4737-4745
[40.]
A.R. West, P.S. Oates.
Mechanisms of heme iron absorption: current questions and controversies.
World J Gastroenterol, 14 (2008), pp. 4101-4110
[41.]
T. Ganz, E. Nemeth.
Iron imports. IV. Hepcidin and regulation of body iron metabolism.
Am J Physiol Gastrointest Liver Physiol, 290 (2006), pp. G199-G203
[42.]
M.F. Macedo, M. De Sousa.
Transferrin and the transferrin receptor: of magic bullets and other concerns.
Inflamm Allergy Drug Targets, 7 (2008), pp. 41-52
[43.]
E. Nemeth.
Iron regulation erythropoiesis.
Curr Opin Hematol, 15 (2008), pp. 169-175
[44.]
T. Ganz.
Hepcidin and its role in regulating systemic iron metabolism.
Hematology Am Soc Hematol Educ Program, (2006), pp. 29-35
[45.]
J.J. Alonso, A. Cánovas, R. De la Prieta, T. Pereira, C. Ruiz, C. Aguirre.
Conceptos generales sobre el metabolismo del hierro.
Gac Med Bilbao, 99 (2002), pp. 33-37
[46.]
J.B. Wish.
Assessing iron status: beyond serum ferritin transferrin saturation.
Clin J Am Soc Nephrol, 1 (2006), pp. S4-S8
[47.]
N. Ternes, B. Scheiber-Mojdehkar, G. Landgraf, H. Goldenberg, B. Sturm.
Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages.
Nephrol Dial Transplant, 22 (2007), pp. 2824-2830
[48.]
G.R. Aronoff.
Safety of intravenous iron in clinical practice: implications for anemia management protocols.
J Am Soc Nephrol, 15 (2004), pp. S99-S106
[49.]
M. Piagnerelli, A. Rapotec, F. Cotton, J.L. Vincent.
Iron administration in the critically ill.
Semin Hematol, 43 (2006), pp. S23-S27
[50.]
N.P. Mena, A. Esparza, V. Tapia, P. Valdés, M.T. Núñez.
Hepcidin inhibits apical iron uptake in intestinal cells.
Am J Physiol Gastrointest Liver Physiol, 294 (2008), pp. G192-G198
[51.]
M. Hoppe, B. Lönnerdal, B. Hossain, S. Olsson, F. Nilsson, P.A. Lundberg, et al.
Hepcidin, interleukin-6 and hematological iron markers in males before and after heart surgery.
J Nutr Biochem, 20 (2009), pp. 11-16
[52.]
E. Nemeth, S. Rivera, V. Gabayan, C. Keller, S. Taudorf, B.K. Pedersen, et al.
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.
J Clin Invest, 113 (2004), pp. 1271-1276
[53.]
F. Canonne-Hergaux, A. Donovan, C. Delaby, H.J. Wang, P. Gros.
Comparative studies of duodenal and macrophage ferroportin proteins.
Am J Physiol Gastrointest Liver Physiol, 290 (2006), pp. G156-G163
[54.]
S. Yamaji, P. Sharp, B. Ramesh, S.K. Srai.
Inhibition of iron transport across human intestinal epithelial cells by hepcidin.
Blood, 104 (2004), pp. 2178-2180
[55.]
T. Chaston, B. Chung, M. Mascarenhas, J. Marks, B. Patel, S.K. Srai, et al.
Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells.
Gut, 57 (2008), pp. 374-382
[56.]
M. Auerbach, D. Coyne, H. Ballard.
Intravenous iron: from anathema to standard of care.
Am J Hematol, 83 (2008), pp. 580-588
[57.]
B.S. Skikne.
Serum transferring receptor.
Am J Hematol, 83 (2008), pp. 872-875
[58.]
R. Zarychanski, D.S. Houston.
Anemia of chronic disease: a harmful disorder or an adaptive beneficial response?.
CMAJ, 179 (2008), pp. 333-337
[59.]
G. Weiss, L.T. Goodnough.
Anemia of chronic disease.
N Engl J Med, 352 (2005), pp. 1011-1023
[60.]
L. Tacchini, E. Gammella, C. De Ponti, S. Recalcati, G. Cairo.
Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals.
J Biol Chem, 283 (2008), pp. 20674-20686
[61.]
D.H. Henry.
The role of intravenous iron in cancer-related anemia.
Oncology (Williston Park), 20 (2006), pp. 21-24
[62.]
J. Cuenca, J.A. García-Erce, M. Muñoz, M. Izuel, A.A. Martínez, A. Herrera.
Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study.
Transfusion, 44 (2004), pp. 1447-1452
[63.]
P. Beris, A. Maniatis.
Role of intravenous iron therapy in anemia management: state of the art.
Semin Hematol, 43 (2006), pp. S1-S2
[64.]
M. Muñoz, A. Campos, J.A. García-Erce.
Intravenous iron in colorrectal cancer surgery.
Semin Hematol, 43 (2006), pp. S36-S38
[65.]
C. Miki, J. Hiro, E. Ojima, Y. Inoue, Y. Mohri, M. Kusunoki.
Perioperative allogeneic blood transfusion, the related cytokine response and long-term survival after potentially curative resection of colorectal cancer.
Clin Oncol (R Coll Radiol), 18 (2006), pp. 60-66
[66.]
A. Shander, K. Knight, R. Thurer, J. Adamson, R. Spence.
Prevalence and outcomes of anemia in surgery: a systematic review of the literature.
Am J Med, 116 (2004), pp. 58S-69S
[67.]
S.S. Chang, J.A. Smith, N. Wells, M. Peterson, B. Kovach, M.S. Cookson.
Estimated blood loss and transfusion requirements of radical cystectomy.
J Urol, 166 (2001), pp. 2151-2154
[68.]
N. Padullés, F. Sala, L. Mendarte, J. Monterde.
Fisiopatología del hierro. Criterios de indicación de hierro parenteral, disponibilidad y pautas de administración. Revisión de la situación actual.
Pharmaceutical Care España, 8 (2006), pp. 199-252
[70.]
C.E. Van Iperen, R.J. Kraaijenhagen, D.H. Biesma, Y. Beguin, J.J. Marx, A. Van de Wiel.
Iron metabolism and erythropoiesis after surgery.
Br J Surg, 85 (1998), pp. 41-45
[71.]
D.H. Biesma, A. Van de Wiel, Y. Beguin, R.J. Kraaijenhagen, J.J. Marx.
Post-operative erythropoiesis is limited by the inflammatory effect of surgery on iron metabolism.
Eur J Clin Invest, 25 (1995), pp. 383-389
[72.]
J.P. Wallis, A.W. Wells, S. Whitehead, N. Brewster.
Recovery from post-operative anaemia.
Transfus Med, 15 (2005), pp. 413-418
[73.]
J.V. Solis, J.L. Portero, J. Diaz, R. Garcia, J.M. Ligero, E. Vazquez, et al.
Iron deficiency in the acute-phase reaction after open aortic surgery.
Vasc Endovascular Surg, 40 (2006), pp. 392-398
[74.]
K. Karkouti, S.A. McCluskey, M. Ghannam, M.J. Salpeter, I. Quirt, T.M. Yau.
Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia.
Can J Anaesth, 53 (2006), pp. 11-19
[75.]
J.R. Dunne, D. Malone, J.K. Tracy, C. Gannon, L.M. Napolitano.
Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery.
J Surg Res, 102 (2002), pp. 237-244
[76.]
M. Aldemir, S. Ozen, I.H. Kara, A. Sir, B. Baç.
Predisposing factors for delirium in the surgical intensive care unit.
Crit Care, 5 (2001), pp. 265-270
[77.]
T. Sagesaka, H. Juen, M. Kaibara.
Anemia as a risk factor of hemorrhagic tendency during surgery.
J Obstet Gynaecol Res, 26 (2000), pp. 103-109
[78.]
M. Horzic, M. Kopljar.
Postoperative infections in colorectal cancer patients.
Hepatogastroenterology, 52 (2005), pp. 101-104
[79.]
J.I. Rodríguez-Hermosa, A. Codina-Cazador, B. Ruiz, J. Roig, J. Gironès, M. Pujadas, et al.
Risk factors for acute abdominal wall dehiscence after laparotomy in adults.
Cir Esp, 77 (2005), pp. 280-286
[80.]
J. Höer, G. Lawong, U. Klinge, V. Schumpelick.
Factors influencing the development of incisional hernia. A retrospective study of 2,983 laparotomy patients over a period of 10 years.
Chirurg, 73 (2002), pp. 474-480
[81.]
D.L. Malone, T. Genuit, J.K. Tracy, C. Gannon, L.M. Napolitano.
Surgical site infections: reanalysis of risk factors.
J Surg Res, 103 (2002), pp. 89-95
[82.]
J.T. Mäkelä, H. Kiviniemi, T. Juvonen, S. Laitinen.
Factors influencing wound dehiscence after midline laparotomy.
Am J Surg, 170 (1995), pp. 387-390
[83.]
F. Schmidtler, F.W. Schildberg, W. Schramm, C. Gleisner.
The pathogenesis of postoperative abdominal wound dehiscence. Part I: Clinical investigations to determine patient groups at risk (author's transl).
MMW Munch Med Wochenschr, 119 (1977), pp. 685-689
[84.]
V. Velanovich.
Innovative use of quality-of-life data: correlating physiologic parameters with patient-centered symptoms−the example of anemia on the vitality of surgical oncology patients.
Surg Innov, 15 (2008), pp. 47-51
[85.]
M. Dunkelgrun, S.E. Hoeks, G.M. Welten, R. Vidakovic, T.A. Winkel, O. Schouten, et al.
Anemia as an independent predictor of perioperative and long-term cardiovascular outcome in patients scheduled for elective vascular surgery.
Am J Cardiol, 101 (2008), pp. 1196-1200
[86.]
B. Dietl, J. Marienhagen, C. Schäfer, O. Kölbl.
The prognostic value of anaemia at different treatment times in patients with locally advanced head and neck cancer treated with surgery and postoperative radiotherapy.
Clin Oncol (R Coll Radiol), 19 (2007), pp. 228-233
[87.]
M. Muñoz, C. Breymann, J.A. García-Erce, S. Gómez-Ramírez, J. Comin, E. Bisbe.
Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion.
Vox Sang, 94 (2008), pp. 172-183
[88.]
J. Cuenca, J.A. García-Erce, A.A. Martínez, V.M. Solano, J. Molina, M. Muñoz.
Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data.
Arch Orthop Trauma Surg, 125 (2005), pp. 342-347
[89.]
M. Muñoz, J.V. Llau, S.R. Leal, J.A. García-Erce, J.M. Culebras.
Transfusión sanguínea perioperatoria en el paciente neoplásico (II). Alternativas para la reducción de los riesgos transfusionales.
Cir Esp, 72 (2002), pp. 337-348
[90.]
P. Heras, K. Kritikos, A. Hatzopoulos, D. Mitsibounas.
Onceweekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Eur J Cancer Care (Engl), 17 (2008), pp. 619-623
[91.]
J. Griniatsos, I. Papaconstantinou, E. Felekouras, P.O. Michail, C. Bakoyiannis, J. Bramis.
The significance of perioperative anemia in patients with resectable gastrointestinal tract tumors.
J BUON, 9 (2004), pp. 247-253
[92.]
M. Christodoulakis, D.D. Tsiftsis.
Hellenic Surgical Oncology Perioperative EPO Study Group. Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study.
Ann Surg Oncol, 12 (2005), pp. 718-725
[93.]
J. Kim, V. Konyalian, R. Huynh, R. Mittal, M. Stamos, R. Kumar.
Identification of predictive factors for perioperative blood transfusion in colorectal resection patients.
Int J Colorectal Dis, 22 (2007), pp. 1493-1497
[94.]
S.J. Papini-Berto, R.C. Burini.
Causes of malnutrition in postgastrectomy patient.
Arq Gastroenterol, 38 (2001), pp. 272-275
[95.]
M. Delgado, C. Gómez, A.I. Cos, C. Iglesias, M.V. Fernández, R. Castillo, et al.
Evaluación nutricional en pacientes con gastrectomía total.
Nutr Hosp, 17 (2002), pp. 236-239
[96.]
E.C. Mimura, J.W. Breganó, J.B. Dichi, E.P. Gregório, I. Dichi.
Comparison of ferrous sulfate and ferrous glycinate chelate for the treatment of iron deficiency anemia in gastrectomized patients.
Nutrition, 24 (2008), pp. 663-668
[97.]
C. Beyan, E. Beyan, K. Kaptan, A. Ifran, A.I. Uzar.
Post-gastrectomy anemia: evaluation of 72 cases with post-gastrectomy anemia.
Hematology, 12 (2007), pp. 81-84
[98.]
R. Calpena, L. Bellot, M.T. Pérez-Vázquez, A. Compañ, J. Del Fresno, P. Serrano, et al.
Metabolic disorders in the gastrectomized patient.
Rev Esp Enferm Dig, 78 (1990), pp. 278-282
[99.]
S. Adachi, T. Kawamoto, M. Otsuka, T. Todoroki, K. Fukao.
Enteral vitamin B12 supplements reverse postgastrectomy B12 deficiency.
Ann Surg, 232 (2000), pp. 199-201
[100.]
M. Javier, A. Loarte, P. Pilco.
Evaluación nutricional en pacientes con gastrectomía total y parcial por adenocarcinoma gástrico.
Rev Gastroenterol Perú, 28 (2008), pp. 239-243
[101.]
J.S. Hahn, D.K. Nam, E.J. Lee, S.J. Lee, Y.W. Ko, I.N. Sunwoo, et al.
A case of vitamin B12 deficiency megaloblastic anemia following total gastrectomy.
Yonsei Med J, 29 (1988), pp. 270-277
[102.]
M. Muñoz, M.J. Ruiz, S. García, J. García, A. Campos, G. Ramírez.
Prevalencia de anemia y deficiencias de hematínicos en pacientes sometidos a cirugía bariátrica en un hospital universitario.
Anemia (Anemia Working Group Iberoamérica), 1 (2008), pp. 14-21
[103.]
A.L. Love, H.H. Billett.
Obesity, bariatric surgery and iron deficiency: true, true, and true related.
Am J Hematol, 83 (2008), pp. 403-409
[104.]
R.E. Brolin, J.H. Gorman, R.C. Gorman, A.J. Petschenik, L.B. Bradley, H.A. Kenler, et al.
Prophylactic iron supplementation after Roux-en-Y gastric bypass: a prospective, double-blind, randomized study.
Arch Surg, 133 (1998), pp. 740-744
[105.]
J.I. Alvarez-Leite.
Nutrient deficiencies secondary to bariatric surgery.
Curr Opin Clin Nutr Metab Care, 7 (2004), pp. 569-575
[106.]
J. Ocón, S. Pérez, S. Gimeno, P. Benito, R. García.
Effectiveness and complications of bariatric surgery in the treatment of morbid obesity.
Nutr Hosp, 20 (2005), pp. 409-414
[107.]
S. Varma, W. Baz, E. Badine, F. Nakhl, H. McMullen, J. Nicastro, et al.
Need for parenteral iron therapy after bariatric surgery.
Surg Obes Relat Dis, 4 (2008), pp. 715-719
[108.]
M.A. Marinella.
Anemia following Roux-en-Y surgery for morbid obesity: a review.
South Med J, 101 (2008), pp. 1024-1031
[109.]
A. Sitges-Serra, J.J. Insenser, E. Membrilla.
Blood transfusions and postoperative infections in patients undergoing elective surgery.
Surg Infect (Larchmt), 7 (2006), pp. S33-S35
[110.]
I. Bates, G.K. Chapotera, S. McKew, N. Van den Broek.
Maternal mortality in sub-Saharan Africa: the contribution of ineffective blood transfusion services.
BJOG, 115 (2008), pp. 1331-1339
[111.]
F. Rovera, G. Dionigi, L. Boni, A. Imperatori, A. Tabacchi, G. Carcano, et al.
Postoperative infections after oesophageal resections: the role of blood transfusions.
World J Surg Oncol, 4 (2006), pp. 80
[112.]
T.H. Edna, T. Bjerkeset.
Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer.
Dis Colon Rectum, 41 (1998), pp. 451-459
[113.]
T. Mynster, I.J. Christensen, F. Moesgaard, H.J. Nielsen.
Danish RANX05 Colorectal Cancer Study Group. Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer.
Br J Surg, 87 (2000), pp. 1553-1562
[114.]
M.M. Heiss, W. Mempel, C. Delanoff, K.W. Jauch, C. Gabka, M. Mempel, et al.
Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery.
J Clin Oncol, 12 (1994), pp. 1859-1867
[115.]
O.R. Busch, W.C. Hop, M.A. Hoynck van Papendrecht, R.L. Marquet, J. Jeekel.
Blood transfusions and prognosis in colorectal cancer.
N Engl J Med, 328 (1993), pp. 1372-1376
[116.]
J. Griniatsos, I. Papaconstantinou, E. Felekouras, P.O. Michail, C. Bakoyiannis, J. Bramis.
The significance of perioperative anemia in patients with respectable gastrointestinal tract tumors.
J BUON, 9 (2004), pp. 247-253
[117.]
M. Jagoditsch, P. Pozgainer, A. Klingler, J. Tschmelitsch.
Impact of blood transfusions on recurrence and survival after rectal cancer surgery.
Dis Colon Rectum, 49 (2006), pp. 1116-1130
[118.]
D.R. Spahn, M. Casutt.
Eliminating blood transfusions: new aspects and perspectives.
Anesthesiology, 93 (2000), pp. 242-255
[119.]
R. Leal, I. Alberca, M.S. Asuero, J.L. Bóveda, N. Carpio, E. Contreras, et al.
Documento “Sevilla” de consenso sobre alternativas a la transfusión de sangre alogénica.
Med Clin (Barc), 127 (2006), pp. 3-20
[120.]
J.S. Jahr, V. Walker, K. Manoochehri.
Blood substitutes as pharmacotherapies in clinical practice.
Curr Opin Anaesthesiol, 20 (2007), pp. 325-330
[121.]
R.S. Weber, N. Jabbour.
Martin 2nd RC. Anemia and transfusions in patients undergoing surgery for cancer.
Ann Surg Oncol, 15 (2008), pp. 34-45
[122.]
C. Madjdpour, V. Heindl, D.R. Spahn.
Risks, benefits, alternatives and indications of allogenic blood transfusions.
Minerva Anestesiol, 72 (2006), pp. 283-298
[123.]
D. Strumper-Groves.
Perioperative blood transfusion and outcome.
Curr Opin Anaesthesiol, 19 (2006), pp. 198-206
[124.]
L.T. Goodnough, A. Shander, R. Spence.
Bloodless medicine: clinical care without allogeneic blood transfusion.
Transfusion, 43 (2003), pp. 668-676
[125.]
A. Shander.
Surgery without blood.
Crit Care Med, 31 (2003), pp. S708-S714
[126.]
L.T. Goodnough, M.E. Brecher, M.H. Kanter, J.P. AuBuchon.
Transfusion medicine. First of two parts−blood transfusion.
N Engl J Med, 340 (1999), pp. 438-447
[127.]
L.T. Goodnough, M.E. Brecher, M.H. Kanter, J.P. AuBuchon.
Transfusion medicine. Second of two parts--blood conservation.
N Engl J Med, 340 (1999), pp. 525-533
[128.]
P.C. Hébert, G. Wells, M.A. Blajchman, J. Marshall, C. Martin, G. Pagliarello, et al.
Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care.
N Engl J Med, 340 (1999), pp. 409-417
[129.]
H.L. Corwin, J.L. Carson.
Blood transfusion−When is more really less?.
N Engl J Med, 356 (2007), pp. 1667-1669
[130.]
L.M. Napolitano.
Current status of blood component therapy in surgical critical care.
Curr Opin Crit Care, 10 (2004), pp. 311-317
[131.]
W.B. Gilbert, J.A. Smith.
Blood use strategies in urologic surgery.
Urology, 55 (2000), pp. 461-467
[132.]
M. Braga, L. Gianotti, O. Gentilini, A. Vignali, V. Di Carlo.
Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery.
Hepatogastroenterology, 44 (1997), pp. 685-690
[133.]
E.W. Weber, R. Slappendel, Y. Hémon, S. Mähler, T. Dalén, E. Rouwet, et al.
Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST).
Eur J Anaesthesiol, 22 (2005), pp. 249-257
[134.]
J.E. Santoro, R.K. Eastlack, J.M. Mirocha, W.D. Bugbee.
Impact of erythropoietin on allogenic blood exposure in orthopedic surgery.
Am J Orthop, 36 (2007), pp. 600-604
[135.]
N. Kosmadakis, E. Messaris, A. Maris, S. Katsaragakis, E. Leandros, M.M. Konstadoulakis, et al.
Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study.
Ann Surg, 237 (2003), pp. 417-421
[136.]
B.G. Feagan, C.J. Wong, A. Kirkley, D.W. Johnston, F.C. Smith, P. Whitsitt, et al.
Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial.
Ann Intern Med, 133 (2000), pp. 845-854
[137.]
M. Braga, L. Gianotti, A. Vignali, O. Gentilini, P. Servida, C. Bordignon, et al.
Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract.
Br J Surg, 82 (1995), pp. 1637-1640
[138.]
M. Braga, L. Gianotti, O. Gentilini, A. Vignali, L. Corizia, V. Di Carlo.
Erythropoiesis after therapy with recombinant human erythropoietin: a dose-response study in anemic cancer surgery patients.
Vox Sang, 76 (1999), pp. 38-42
[139.]
N. Qvist, S. Boesby, B. Wolff, C.P. Hansen.
Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: reduced need for blood transfusions in patients undergoing colorectal surgery−prospective double-blind placebo-controlled study.
World J Surg, 23 (1999), pp. 30-35
[140.]
E.A. Levine, C. Laborde, E. Hambrick, C.A. McKnight, S. Vijayakumar.
Influence of erythropoietin on transfusion requirements in patients receiving preoperative chemoradiotherapy for rectal cancer.
Dis Colon Rectum, 42 (1999), pp. 1065-1069
[141.]
N. Rosenblum, M.A. Levine, T. Handler, H. Lepor.
The role of preoperative epoetin alfa in men undergoing radical retropubic prostatectomy.
J Urol, 163 (2000), pp. 829-833
[142.]
R.M. Gall, P.D. Kerr.
Use of preoperative erythropoietin in head and neck surgery.
J Otolaryngol, 29 (2000), pp. 131-134
[143.]
Y. Tsuji, J. Kambayashi, E. Shiba, M. Sakon, T. Kawasaki, T. Mori.
Effect of recombinant human erythropoietin on anaemia after gastrectomy: a pilot study.
Eur J Surg, 161 (1995), pp. 29-33
[144.]
G. Gargano, G. Polignano, M. De Lena, M. Brandi, V. Lorusso, G. Fanizza.
The utility of a growth factor: r-HuEPO as a treatment for preoperative autologous blood donation in gynecological tumor surgery.
Int J Oncol, 14 (1999), pp. 157-160
[145.]
N. Shinozuka, I. Koyama, T. Arai, Y. Numajiri, T. Watanabe, et al.
Autologous blood transfusion in patients with hepatocellular carcinoma undergoing hepatectomy.
Am J Surg, 179 (2000), pp. 42-45
[146.]
S. Nakai, H. Yoshizawa, S. Kobayashi, K. Naga, H. Ichinose.
Role of autologous blood transfusion in sacral tumor resection: patient selection and recovery after surgery and blood donation.
J Orthop Sci, 5 (2000), pp. 321-327
[147.]
B. Michaeli, P. Ravussin, P.G. Chassot.
Autologous blood predonation and perioperative use of erythropoietin.
Rev Med Suisse, 2 (2006), pp. 2662-2664
[148.]
J.F. Baron.
Autologous blood donation with recombinant human erythropoietin in cardiac surgery: the Japanese experience.
Semin Hematol, 33 (1996), pp. 64-67
[149.]
M. Tryba.
Epoetin alfa plus autologous blood donation and normovolemic hemodilution in patients scheduled for orthopedic or vascular surgery.
Semin Hematol, 33 (1996), pp. 34-36
[150.]
T. Konishi, T. Kaneko, T. Ohbayashi, T. Ohki, Y. Watanabe, K. Fuse.
Effectiveness of erythropoietin for cardiovascular surgery to prevent homologous blood transfusions.
Nippon Kyobu Geka Gakkai Zasshi, 41 (1993), pp. 187-192
[151.]
M. Okuyama, K. Ikeda, T. Shibata, Y. Tsukahara, M. Kitada, T. Shimano.
Preoperative iron supplementation and intraoperative transfusion during colorectal cancer surgery.
Surg Today, 35 (2005), pp. 36-40
[152.]
D.B. Van Wyck, M.G. Martens, M.H. Seid, J.B. Baker, A. Mangione.
Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
Obstet Gynecol, 110 (2007), pp. 267-278
[153.]
C. Breymann, F. Gliga, C. Bejenariu, N. Strizhova.
Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.
Int J Gynaecol Obstet, 101 (2008), pp. 67-73
[154.]
G. Perewusnyk, R. Huch, A. Huch, C. Breymann.
Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex.
Br J Nutr, 88 (2002), pp. 3-10
[155.]
C. Gasche, C. Dejaco, T. Waldhoer, W. Tillinger, W. Reinisch, G.F. Fueger, et al.
Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial.
Ann Intern Med, 126 (1997), pp. 782-787
[156.]
M. Muñoz, E. Naveira, J. Seara, J.H. Palmer, J. Cuenca, J.A. García- Erce.
Role of parenteral iron in transfusion requirements after total hip replacement. A pilot study.
Transfus Med, 16 (2006), pp. 137-142
[157.]
E. Gredilla, M. Gimeno, E. Canser, B. Martínez, F.A. Pérez, F. Gilsanz.
Postpartum and early postoperative anemia after gynecological surgery: treatment with intravenous iron.
Rev Esp Anestesiol Reanim, 53 (2006), pp. 208-213
[158.]
J. Cuenca, J.A. García-Erce, F. Martínez, L. Pérez-Serrano, A. Herrera, M. Muñoz.
Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after knee replacement surgery.
Transfusion, 46 (2006), pp. 1112-1119
[159.]
M.M. Del Trujillo, A. Carrero, M. Muñoz.
The utility of the perioperative autologous transfusion system OrthoPAT® in total hip replacement surgery: a prospective study.
Arch Orthop Trauma Surg, 128 (2008), pp. 1031-1038
[160.]
P. Carless, A. Moxey, D. O’Connell, D. Henry.
Autologous transfusion techniques: a systematic review of their efficacy.
Transfus Med, 14 (2004), pp. 123-144
[161.]
G. Chen, F.J. Zhang, M. Gong, M. Yan.
Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients.
J Zhejiang Univ Sci B, 8 (2007), pp. 560-565
[162.]
M. Takemura, H. Osugi, M. Higashino, N. Takada, S. Lee, H. Kinoshita.
Effect of substituting allogenic blood transfusion with autologous blood transfusion on outcomes after radical oesophagectomy for cancer.
Ann Thorac Cardiovasc Surg, 11 (2005), pp. 293-300
[163.]
K.G. Mercer, J.I. Spark, D.C. Berridge, P.J. Kent, D.J. Scott.
Randomized clinical trial of intraoperative autotransfusion in surgery for abdominal aortic aneurysm.
Br J Surg, 91 (2004), pp. 1443-1448
[164.]
Y. Kinoshita, H. Udagawa, K. Tsutsumi, M. Ueno, T. Nakamura, H. Akiyama, et al.
Usefulness of autologous blood transfusion for avoiding allogenic transfusion and infectious complications after esophageal cancer resection.
Surgery, 127 (2000), pp. 185-192
[165.]
H. Komai, Y. Naito, Y. Iwasaki, M. Iwahashi, K. Fujiwara, Y. Noguchi.
Autologous blood donation with recombinant human erythropoietin for abdominal aortic aneurysm surgery.
Surg Today, 30 (2000), pp. 511-515
[166.]
A.T. Tinmouth, L.A. McIntyre, R.A. Fowler.
Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients.
CMAJ, 178 (2008), pp. 49-57
[167.]
J.G. Perkins, A.P. Cap, B.M. Weiss, T.J. Reid, C.E. Bolan.
Massive transfusion and nonsurgical hemostatic agents.
Crit Care Med, 36 (2008), pp. S325-S339
[168.]
P.M. Mannucci, M. Levi.
Prevention and treatment of major blood loss.
N Engl J Med, 356 (2007), pp. 2301-2311
[169.]
A.M. Mahdy, N.R. Webster.
Perioperative systemic haemostatic agents.
Br J Anaesth, 93 (2004), pp. 842-858
[170.]
C. Lentschener, D. Benhamou, F.J. Mercier, C. Boyer-Neumann, S. Naveau, C. Smadja, et al.
Aprotinin reduces blood loss in patients undergoing elective liver resection.
Anesth Analg, 84 (1997), pp. 875-881
[171.]
J.A. Páramo, R. Lecumberri, M. Hernández, E. Rocha.
Alternativas farmacológicas a la transfusión sanguínea. ¿Qué hay de nuevo?.
Med Clin (Barc), 122 (2004), pp. 231-236
[172.]
F.D. Cushner.
Transfusion avoidance in orthopedic surgery.
J Cardiothorac Vasc Anesth, 18 (2004), pp. 29S-30S
[173.]
D.A. Fergusson, P.C. Hébert, C.D. Mazer, S. Fremes, C. MacAdams, J.M. Murkin, et al.
A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
N Engl J Med, 358 (2008), pp. 2319-2331
[174.]
I.S. Fraser, R.J. Porte, P.A. Kouides, A.S. Lukes.
A benefit-risk review of systemic haemostatic agents: part 1: in mayor surgery.
Drug Saf, 31 (2008), pp. 217-230
[175.]
K. Oka, H. Tsuda, K. Kamikaseda, R. Nakamura, M. Fukui, Y. Nouzuka, et al.
Meningiomas and hemorrhagic diathesis.
J Neurosurg, 69 (1988), pp. 356-360
[176.]
P.L. Martin-Hirsch, H. Kitchener.
Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia.
Cochrane Database Syst Rev, (2000),
[177.]
D. Oertli, U. Laffer, F. Haberthuer, U. Kreuter, F. Harder.
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Br J Surg, 81 (1994), pp. 856-859
[178.]
P.A. Everts, J.T. Knape, G. Weibrich, J.P. Schönberger, J. Hoffmann, E.P. Overdevest, et al.
Platelet-rich plasma and platelet gel: a review.
J Extra Corpor Technol, 38 (2006), pp. 174-187
[179.]
D.R. Spahn, R. Kocian.
Artificial O2 carriers: status in 2005.
Curr Pharm Des, 11 (2005), pp. 4099-4114
[180.]
B. Remy, G. Deby-Dupont, M. Lamy.
Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions.
Br Med Bull, 55 (1999), pp. 277-298
[181.]
D.R. Spahn, K.F. Waschke, T. Standl, J. Motsch, L. Van Huynegem, M. Welte, et al.
Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study.
Anesthesiology, 97 (2002), pp. 1338-1349
[182.]
C. Natanson, S.J. Kern, P. Lurie, S.M. Banks, S.M. Wolfe.
Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis.
JAMA, 299 (2008), pp. 2304-2312
[183.]
J.S. Jahr, C. Mackenzie, L.B. Pearce, A. Pitman, A.G. Greenburg.
HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery.
J Trauma, 64 (2008), pp. 1484-1497
[184.]
J.H. Levy, L.T. Goodnough, P.E. Greilich, G.V. Parr, R.W. Stewart, I. Gratz, et al.
Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial.
J Thorac Cardiovasc Surg, 124 (2002), pp. 35-42
[185.]
J.S. Jahr, M. Moallempour, J.C. Lim.
HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation).
Expert Opin Biol Ther, 8 (2008), pp. 1425-1433
Copyright © 2010. Asociación Española de Cirujanos
